--- title: BioCity & Oxford AHSN partner to accelerate life science businesses in the golden triangle description: The strategic partnership between Oxford AHSN, who operate in the heart of the regional ecosystem, and BioCity, aims to strengthen collaboration and focus on scaling and sustaining the human and clini image: https://news.lifesciencenewswire.com/hubfs/Imported_Blog_Media/BioCity-and-Oxford-AHSN-Partner-to-Accelerate-Life-Science-Businesses-in-the-Golden-Triangle-1024x512.png --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [BioCity & Oxford AHSN partner to accelerate life science businesses in the golden triangle](https://news.lifesciencenewswire.com/newsroom/biotechnology/biocity-oxford-ahsn-partner-to-accelerate-life-science-businesses-in-the-golden-triangle) July 17, 2019 BioCity, a pioneering life science incubator and business collective, has announced a new strategic partnership with Oxford AHSN. Working in partnership, the Oxford Academic Health Science Network and BioCity are launching a new Accelerator Programme in Berkshire and South Oxfordshire to catalyse growth in Thames Valley’s world-class health and life sciences cluster by supporting the development of start-ups, spin-outs and growth companies across the region’s research, clinical and commercial base. The announcement of a Berkshire and South Oxfordshire-based Accelerator marks a first for BioCity, who have until this point, operated outside the ‘golden triangle’. Seen as a key area for life sciences in the UK, the ‘golden triangle’ is an unofficial grouping of research universities located in Cambridge, Oxford, Milton Keynes, and London. The strategic partnership between Oxford AHSN, who operate in the heart of the regional ecosystem, and BioCity, aims to strengthen collaboration and focus on scaling and sustaining the human and clinical impact of meaningful innovations. [![BioCity and Oxford AHSN Partner to Accelerate Life Science Businesses in the Golden Triangle](https://news.lifesciencenewswire.com/hs-fs/hubfs/Imported_Blog_Media/BioCity-and-Oxford-AHSN-Partner-to-Accelerate-Life-Science-Businesses-in-the-Golden-Triangle-1024x512.png?width=1024&height=512&name=BioCity-and-Oxford-AHSN-Partner-to-Accelerate-Life-Science-Businesses-in-the-Golden-Triangle-1024x512.png)](https://news.lifesciencenewswire.com/hubfs/Imported_Blog_Media/BioCity-and-Oxford-AHSN-Partner-to-Accelerate-Life-Science-Businesses-in-the-Golden-Triangle-e1564153817484.png) The announcement further cements BioCity’s position as a leader in entrepreneur coaching within the life sciences. Using contemporary concepts and Lean Start-up methods, BioCity, who run entrepreneur coaching across their UK locations, also frequently deliver accelerators on behalf of industry partners, including Opportunity North East (ONE) in Aberdeen and The Biosphere, Newcastle. The BioCity Accelerator has a proven track record. To date, over one hundred science entrepreneurs have graduated from the coaching programme before successfully launching life science businesses, securing investment, both via and independent of the BioCity investment fund, and attracting industry recognition. Colin Roberts, BioCity venture development director, said, “This is a new geographic area for BioCity, we’re excited to discover some of the new ideas and work with new ventures on our first Accelerator in Oxfordshire and Berkshire. “The strategic goals of Oxford AHSN are closely aligned with ours; together, we’ll be able to achieve our shared goal of supporting life science innovation at a regional level.” At the completion of taster workshops focused on commercialisation with a cohort of twelve entrepreneurs and start-ups, Paul Durrands, the Chief Operating Officer of the Oxford AHSN said, ‘‘In our pursuit to build a business case for change, our collaboration with delivery partners such as BioCity is already making a good impact’’. The Oxford AHSN has a leading national and international health and life sciences cluster, home to a rich and diverse community of innovators, entrepreneurs, researchers and healthcare providers. The Oxford AHSN provides expert support along the entire health innovation pathway, from ideation, through prototype testing, system viability on to adoption. It fosters long term partnerships with industry, a culture of innovation in the NHS and economic growth, securing £123M of investment into the region to date. Highly sought after, entrepreneurs will be awarded a place on the Accelerator after first taking part in a pre-accelerator, held 02 – 04 September 2019. To find out more visit [https://biocity.co.uk/accelerator-programmes/](https://biocity.co.uk/accelerator-programmes/)   **About BioCity** Home to more than 200 companies, BioCity is a pioneering life science incubator and business collective. Where ideas become reality, investment flows and businesses succeed. Not the typical business incubator, BioCity takes a holistic approach to business support. Offering entrepreneur coaching, investment, flexible lab and office space and PAYG services within a UK-wide business collective.   Founded in 2002 by the University of Nottingham and Nottingham Trent University, BioCity originated in a former BASF Pharma research facility in Nottingham city centre. In 2012 BioCity acquired the MSD research facility in Newhouse near Glasgow to create Glasgow, BioCity. This was closely followed by a second site in Nottingham, MediCity, which is located on the Boots campus and is a collaboration with Walgreens Boots Alliance. In 2016 the Newhouse site was further expanded to create Glasgow, MediCity. BioCity also operates at Alderley Park, Cheshire, Aberdeen and Newcastle. The company has made 28 investments in early stage companies and has delivered a healthy growth in portfolio valuation. Funds are deployed from its own cash reserves and from a joint venture vehicle with AstraZeneca which BioCity manages. In 2017, BioCity was identified as one of Europe’s fastest growing companies in the Financial Times’ FT 1000 report. The BioCity model of ‘support from inception to incorporation’ initially challenged the industry standard but quickly became the industry leader due to the unprecedented survival rates of BioCity based businesses. For more information visit [https://biocity.co.uk/about](https://biocity.co.uk/about) **About Oxford AHSN** The Oxford Academic Health Science Network (Oxford AHSN) gets innovation into clinical practice to improve patient safety, outcomes and experience, and generate economic growth through collaboration between the NHS, industry and universities. We cover a region of three million people living in Berkshire, Buckinghamshire, Milton Keynes and Oxfordshire. For more information, visit [https://www.oxfordahsn.org/](https://www.oxfordahsn.org/) Categories: [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Research](https://news.lifesciencenewswire.com/newsroom/tag/research), [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [General Science](https://news.lifesciencenewswire.com/newsroom/tag/general-science), [Corporate, Finance & Investor](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) ##### Browse more news ## Recent releases #### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) July 6, 2026 Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) #### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) June 16, 2026 New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) #### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) June 16, 2026 Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)